StockWatch: Cosmo Surges 40% on Baldness Candidate’s Phase III Data
Images of the scalps of two patients treated with the 5% formulation of Cosmo Pharmaceuticals’ androgenetic alopecia (AGA) candidate clascoterone—both during their first visits, and their seventh visits after six…







